Vol. 3 No. 5 (2023)
Reimbursement Reviews

Lutetium (¹⁷⁷Lu) Vipivotide Tetraxetan (Pluvicto)

Published May 18, 2023

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses 177Lu vipivotide tetraxetan (Pluvicto), solution for injection, 1 GBq/mL (27 mCi/mL) at calibration.
  • Indication: The treatment of adults with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer who have received at least 1 androgen receptor pathway inhibitor and taxane-based chemotherapy.